Teleflex launches new Arrow Pressure Injectable Midline Catheter in Europe, the Middle East and Africa region
June 06 2022 - 11:30PM
Teleflex launches new Arrow Pressure Injectable Midline
Catheter in Europe, the Middle East and Africa region
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies, today has announced the launch of an Arrow
Pressure Injectable Midline Catheter in Europe, the Middle East and
Africa region. The addition of the pressure injectable catheter
further enhances the Midline portfolio to meet the expanded needs
of clinicians and is designed to improve patient safety.
The new, 20cm Arrow Pressure Injectable Midline with brightly
colored yellow hubs and labeling, will help clinicians overcome
catheter identification confusion, which can lead to infusion
mistakes that can harm patients. Additional features include:
- Available in 1-lumen and 2-lumen configurations
- TAPERFREE design, which assures consistent French size from
distal tip to catheter hub to reduce the risk of venous stasis.
This design is aligned with INS standards to select a catheter with
a 45% or less catheter to vein ratio from the distal tip to
hub
- Tray configuration designed to facilitate procedural
efficiency
- Arrow Ergonomic trimmer that allows multiple, precise cuts with
its window for easy visualisation of centimeter markings on the
catheter
- Additional sharps safety componentry to meet INS standards
“The new catheter design is a direct result of our partnership
with clinicians and exemplifies how we work together to identify
needs and develop solutions that help them improve patient care,”
said Matthew James, President EMEA for Teleflex. “We are excited to
bring the Arrow Pressure Injectable Midline catheter to the market
here in the region and to expand our portfolio in ways that meet
the many needs of vascular access.”
The new Arrow Pressure Injectable Midline allows for pressure
injection up to 5 mL/second through either lumen to mitigate
diagnostic and treatment delays of having to replace a secondary
device.
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular access, interventional
cardiology and radiology, anesthesia, emergency medicine, surgical,
urology and respiratory care. Teleflex employees worldwide are
united in the understanding that what we do every day makes a
difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow, Deknatel, LMA®, Pilling,
QuikClot, Rüsch, UroLift, and Weck – trusted brands united by a
common sense of purpose.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Deknatel, LMA, Pilling,
QuikClot, Rüsch, UroLift, Weck and TAPERFREE are trademarks or
registered trademarks of Teleflex Incorporated or its affiliates,
in the U.S. and/or other countries.
© 2022 Teleflex Incorporated. All rights reserved. MCI-100825
Rev 1 05 22
Contacts:Teleflex Incorporated:
Lawrence KeuschVice President, Investor Relations and Strategy
Development
John Hsu, CFAVice President, Investor Relations
investors.teleflex.com610-948-2836
Teleflex (TG:TBH)
Historical Stock Chart
From Oct 2024 to Nov 2024
Teleflex (TG:TBH)
Historical Stock Chart
From Nov 2023 to Nov 2024